Amgen’s Wezlana Adds Legal Obstacles to Drug Pricing Battle

Healthcare attorney Melissa Wong was quoted in a Bloomberg Law article about the impacts of biosimilar competitor products now entering the market and how this will affect the Medicare Drug Price Negotiation Program under last year’s Inflation Reduction Act. Ms. Wong commented that the industry is keeping an eye on how the Centers for Medicare & Medicaid Services (CMS) will respond to the development.

“Everyone in the industry is really watching to see how CMS will account for this," Ms. Wong said. 

READ: Amgen’s Wezlana Adds Legal Obstacles to Drug Pricing Battle